Editas Medicine reported its financial results for the second quarter of 2025 on August 12, 2025. The Company's cash, cash equivalents, and marketable securities were $178.5 million as of June 30, 2025, compared to $269.9 million as of December 31, 2024.
The Company expects its existing cash, cash equivalents, marketable securities, and retained portions of Vertex Pharmaceuticals payments, to fund operating expenses and capital expenditure requirements into the second quarter of 2027. Editas Medicine is on track to select its lead in vivo development candidate in September 2025.
The first Investigational New Drug (IND) or Clinical Trial Application (CTA) was accepted for the CD19 HD Allo CAR T program, part of a collaboration with Bristol Myers Squibb, which triggered a milestone payment to Editas. The Company is on track to file an IND for its lead program by mid-2026 and achieve human proof-of-concept by year-end 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.